OBJECTIVES:  The objective of the study was to perform a Budget Impact Analysis (BIA) assessing the introduction of Triveram for the treatment of hypertension into the Italian market. Triveram is a single pill combination of statin (atorvastatin calcium trihydrate), calcium channel blocker (amlodipine besilate) and angiotensin-converting enzyme inhibitor (perindopril arginine) indicated for the treatment of essential hypertension and/or stable coronary artery disease. METHODS:  BIA compared two different scenarios: Scenario 1 without the triple fixed combination therapy vs. Scenario 2 with the introduction of Triveram. Population data were obtained from Local Project Database by Cegedim. The time horizon considered was 3 years from the introduction of Triveram. Total number of patients in each of the 3 years was the same for the two Scenarios, as the model allows only the switch of patients from the dual or triple combinations to the fixed dose treatment with Triveram. The perspective of the Italian National Healthcare Service was considered. RESULTS:  The study showed that the introduction of Triveram leads to a reduction in the quantity of pills taken by patients (247.893.255, 270.691.934 and 287.356.690 in Scenario 1 and 224.916.946, 222.121.000 and 214.892.239 in Scenario 2, respectively in year 1, 2 and 3). At a cost of 12,90 €/month, the introduction of Triveram generates savings for the Italian NHS of 10.6, 22.4 and 33.5 million € respectively in year 1, 2 and 3 over the total expenditure of 95, 114.8 and 126.1 million € related to year 1, 2 and 3 in the first scenario. CONCLUSIONS:  The present study indicates that the introduction of Triveram generates important savings for the Italian NHS and improves the adherence to the therapy, thanks to the reduction in the number of pills taken by patients. Better adherence is also linked to a reduction in the number of hospitalizations and related costs.